Thomas Andrew Crockett Kal Vista Pharmaceuticals, Inc. (KALV) insider trading activity

KALV Quotes by TradingView

Thomas Andrew Crockett is CEO of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 211,203 shares of KALV, which is worth approximately $2.37 Million. The most recent transaction as insider was on Feb 20, 2024, when has been sold 24,888 shares (Common Stock) at a price of $14.11 per share, resulting in proceeds of $351,169. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 211K
0% 3M change
52.21% 12M change
Total Value Held $2.37 Million

Thomas Andrew Crockett Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 20 2024
SELL
Open market or private sale
$351,169 $14.11 p/Share
24,888 Reduced 10.54%
211,203 Common Stock
Feb 17 2024
BUY
Exercise of conversion of derivative security
-
54,415 Added 18.73%
236,091 Common Stock
Feb 14 2024
SELL
Open market or private sale
$875,923 $15.01 p/Share
58,356 Reduced 24.31%
181,676 Common Stock
Feb 11 2024
BUY
Grant, award, or other acquisition
-
122,500 Added 33.79%
240,032 Common Stock
Feb 01 2024
SELL
Open market or private sale
$165,000 $16.5 p/Share
10,000 Reduced 7.84%
117,532 Common Stock
Dec 27 2023
SELL
Open market or private sale
$360,600 $12.02 p/Share
30,000 Reduced 19.04%
127,532 Common Stock
Nov 20 2023
SELL
Open market or private sale
$121,861 $8.23 p/Share
14,807 Reduced 8.59%
157,532 Common Stock
Nov 17 2023
BUY
Exercise of conversion of derivative security
-
33,583 Added 16.31%
172,339 Common Stock
Oct 30 2023
SELL
Bona fide gift
-
8,000 Reduced 5.45%
138,756 Common Stock
Aug 18 2023
SELL
Open market or private sale
$159,619 $10.73 p/Share
14,876 Reduced 9.2%
146,756 Common Stock
Aug 17 2023
BUY
Exercise of conversion of derivative security
-
33,582 Added 17.2%
161,632 Common Stock
May 18 2023
SELL
Open market or private sale
$57,057 $10.14 p/Share
5,627 Reduced 4.21%
128,050 Common Stock
May 17 2023
BUY
Exercise of conversion of derivative security
-
12,750 Added 8.71%
133,677 Common Stock
Feb 17 2023
SELL
Open market or private sale
$51,322 $7.66 p/Share
6,700 Reduced 5.25%
120,927 Common Stock
Feb 17 2023
BUY
Exercise of conversion of derivative security
-
12,749 Added 9.08%
127,627 Common Stock
Nov 18 2022
SELL
Open market or private sale
$9,710 $5.44 p/Share
1,785 Reduced 1.53%
114,878 Common Stock
Nov 17 2022
BUY
Exercise of conversion of derivative security
-
5,805 Added 4.74%
116,663 Common Stock
Sep 02 2022
SELL
Open market or private sale
$22,453 $17.01 p/Share
1,320 Reduced 1.18%
110,858 Common Stock
Aug 17 2022
SELL
Open market or private sale
$26,883 $14.96 p/Share
1,797 Reduced 1.58%
112,178 Common Stock
Aug 17 2022
BUY
Exercise of conversion of derivative security
-
5,805 Added 4.85%
113,975 Common Stock
Jul 02 2022
SELL
Bona fide gift
-
6,500 Reduced 5.48%
112,178 Common Stock
Mar 09 2022
SELL
Open market or private sale
$170,700 $17.07 p/Share
10,000 Reduced 8.02%
114,670 Common Stock
Oct 01 2021
SELL
Open market or private sale
$171,800 $17.18 p/Share
10,000 Reduced 7.43%
124,670 Common Stock
Jul 01 2021
SELL
Open market or private sale
$241,200 $24.12 p/Share
10,000 Reduced 6.91%
134,670 Common Stock
Jun 17 2021
SELL
Open market or private sale
$32,053 $30.04 p/Share
1,067 Reduced 0.73%
144,670 Common Stock
TAC

Thomas Andrew Crockett

CEO
Cambridge, MA

Track Institutional and Insider Activities on KALV

Follow KalVista Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

News

Receive news related to KalVista Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on KALV